THOC1: A Potential Cancer Drug Target and Biomarker (G9984)

Target Name: THOC1

NCBI ID: G9984

THOC1

Other Name(s): THOC1_HUMAN | Nuclear matrix protein p84 | N5 | THO complex subunit 1 | p84N5 | tho1 | hTREX84 | HTREX84 | HPR1 | P84 | THO complex 1 | Tho1 | nuclear matrix protein p84 | P84N5

THOC1: A Potential Cancer Drug Target and Biomarker

THOC1 (THOC1_HUMAN), also known as human exploratory oncogene-1, is a gene that has been identified as a potential drug target for various diseases, including cancer. Its unique feature is its high expression level in human tissues, making it a promising biomarker for cancer diagnosis and treatment.

THOC1 is a member of the human exploratory oncogene family, which includes genes that have been implicated in various types of cancer. This family of genes has been implicated in the development of cancer due to its role in cell signaling pathways that promote tumor growth and survival.

THOC1 is expressed in various human tissues, including blood, skin, heart, and brain. Its expression level is highest in the brain, which suggests that it may be involved in the development and progression of certain types of cancer.

One of the key advantages of THOC1 as a drug target is its high stability. Unlike many other genes whose expression has an impact on tumors, THOC1 has been shown to be highly stable across various human tissues and conditions. This stability makes it a promising candidate for drug targeting, as drug developers can use small molecules or antibodies to target the gene and inhibit its activity.

Another advantage of THOC1 is its potential to be used as a biomarker for cancer diagnosis and treatment. Its high expression level in various human tissues makes it a useful marker for tracking disease progression and response to treatment. This can be important for patients with cancer, as accurate diagnosis and treatment can significantly improve outcomes.

In addition to its potential as a drug target and biomarker, THOC1 is also a promising candidate for cancer vaccines. Cancer vaccines can be used to stimulate an immune response against cancer cells, which can lead to the destruction of cancer tumors. THOC1 has been shown to be expressed in various types of cancer cells, which makes it a promising candidate for cancer vaccines.

In conclusion, THOC1 is a gene that has been identified as a potential drug target for various diseases, including cancer. Its high expression level in human tissues and its potential as a biomarker and cancer vaccine make it a promising candidate for drug development. Further research is needed to fully understand its role in cancer and its potential as a drug.

Protein Name: THO Complex Subunit 1

Functions: Required for efficient export of polyadenylated RNA. Acts as component of the THO subcomplex of the TREX complex which is thought to couple mRNA transcription, processing and nuclear export, and which specifically associates with spliced mRNA and not with unspliced pre-mRNA. TREX is recruited to spliced mRNAs by a transcription-independent mechanism, binds to mRNA upstream of the exon-junction complex (EJC) and is recruited in a splicing- and cap-dependent manner to a region near the 5' end of the mRNA where it functions in mRNA export to the cytoplasm via the TAP/NFX1 pathway. The TREX complex is essential for the export of Kaposi's sarcoma-associated herpesvirus (KSHV) intronless mRNAs and infectious virus production. Regulates transcriptional elongation of a subset of genes. Involved in genome stability by preventing co-transcriptional R-loop formation

The "THOC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about THOC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets